Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
20 October, 2017 23:48 IST
Zydus Cadila gets USFDAs final nod for Desvenlafaxine ER tablets
Source: IRIS | 12 Oct, 2017, 01.10PM
Comments  |  Post Comment

Zydus Cadila has received the final approval from the U.S. Food & Drug Administration (USFDA) to market Desvenlafaxine Extended-Release Tablets, 50 mg and 100 mg. The drug is used to treat major depression and will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 160 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Total volume of shares traded on the bourses today was lower by 52.05% to 600,531 compared with 22-day average volume of 1,252,527.

Shares of the company gained Rs 8.65, or 1.76%, to trade at Rs 500.00. The total volume of shares traded was 34,356 at the BSE (12.58 p.m., Thursday).



Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Sensex ends 194 points lower; Nifty settles at 10,146 - 19-Oct-2017 20:06
Sensex down 78 points; Nifty near 10,200 - 19-Oct-2017 18:52
Sensex, Nifty end flat; Axis Bank, ICICI Bank top losers - 18-Oct-2017 16:29
Suven Life Sciences secures product patent in Singapore - 18-Oct-2017 10:42
Rajesh Bhosale on how to trade in Tata Motors-DVR, Syndicate Bank and LIC Housing Finance - 18-Oct-2017 10:37
Wipro quarterly profit climbs 6% - 18-Oct-2017 10:24
Sensex falls 92 points, Nifty trades at 10,203 - 18-Oct-2017 10:20
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer